Earnings call transcript: Valeo confirms 2026 outlook as Q3 sales slip

Valeo reported Q3 sales of EUR 4.9 billion, down 2.6% like-for-like, but reaffirmed its full-year 2026 guidance and said second-half operating margin and free cash flow should be equivalent to the first half. BRAIN sales rose 8% to EUR 1.2 billion, while POWER sales fell 10%; management is targeting EUR 300 million in annual savings and cited new programs as support for a return to growth in 2027. U.S.-listed shares were down 1.69% at $7.33 in recent trading.

Analysis

The key signal is not BRAIN’s quarterly rebound but the gap between program wins and earnings conversion: launches cited for 2027 can support relative growth in a flat market, but do not yet establish durable group-level margin expansion. Management’s clarified H2 target—equivalent to H1, rather than at least equivalent—limits the near-term upside case. Cost savings may protect the floor, but investors should verify delivery in operating margin and free cash flow rather than capitalize the announced run rate upfront.

Second-order, Valeo’s outperformance in selected regions and BRAIN products may help it defend share against other automotive suppliers; however, OEMs retain leverage to split awards and press pricing, while launch delays can defer supplier revenue even after a win. BMW’s Neue Klasse ramp is a tangible execution marker, not proof that the broader pipeline will convert on schedule. The data-center cooling and drone initiatives remain options, not a basis for valuing the core until commercial scale and economics are disclosed.

Near term, weak European demand and POWER’s decline keep estimate risk asymmetric despite unchanged guidance. Over 1–3 months, watch Q4 BRAIN growth, OEM call-offs, compensation for input-cost inflation, and H2 cash delivery. Over 6–18 months, the thesis depends on program ramps lifting organic growth without margin dilution. The contrarian point: the market may be treating BRAIN’s growth as a group inflection too early; equally, treating the POWER decline as purely a comparison effect may understate demand and mix risk. No compelling outright trade on this release alone.

Key Decisions for Investors

• Keep FR on a catalyst watchlist rather than adding on the BRAIN headline. Reassess after Q4 results: sustained BRAIN growth alongside confirmed H2 operating margin and free cash flow would strengthen the 2027 recovery case.
• Do not underwrite the EUR 300 million savings target or new-program wins as earnings until reported results show realized savings and launches translate into revenue and cash. Verify customer compensation timing and any working-capital drag.
• Falsify the recovery thesis if BRAIN growth stalls, European or North American call-offs materially weaken, or H2 margin/free cash flow falls short of management’s stated equivalence to H1. Conversely, successful BMW, Renault, GM and Nissan ramps would be a medium-term positive, subject to disclosed conversion and mix.